219 related articles for article (PubMed ID: 10501822)
1. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
3. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C
Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
Hatorp V; Oliver S; Su CA
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
Hatorp V
Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Bidstrup TB; Stilling N; Damkier P; Scharling B; Thomsen MS; Brøsen K
Eur J Clin Pharmacol; 2004 Apr; 60(2):109-14. PubMed ID: 15034704
[TBL] [Abstract][Full Text] [Related]
11. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
12. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
13. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
14. Rifampin decreases the plasma concentrations and effects of repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
16. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
17. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
18. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
Hatorp V; Huang WC; Strange P
J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
